Ab Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

15.80EUR
24 Apr 2015
Change (% chg)

€0.24 (+1.54%)
Prev Close
€15.56
Open
€15.65
Day's High
€16.08
Day's Low
€15.50
Volume
73,665
Avg. Vol
147,397
52-wk High
€18.93
52-wk Low
€7.16

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.20
Market Cap(Mil.): €519.76
Shares Outstanding(Mil.): 33.40
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 41.04 41.69
EPS (TTM): -0.47 -- --
ROI: -61.99 16.81 16.15
ROE: -- 17.31 16.96
Search Stocks

BRIEF-Results of Ab Science's Masitinib treatment to be published in Annals of Oncology

* The phase III results of the Masitinib treatment of advanced pancreatic cancer to be published in Annals of Oncology Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2015

BRIEF-Ab Science DSMB recommends continuation of phase II Masitinib study

* Announces that DSMB recommends the continuation of phase 2 study assessing Masitinib in relapsing head and neck cancer

30 Mar 2015

BRIEF-Ab Science's Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

* Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

20 Mar 2015

BRIEF-AB Science announces positive phase 2 clinical study of Masitinib

* Announces positive efficacy and safety results from phase 2 study with Masitinib in patients with triple negative breast cancer (TNBC) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Mar 2015

BRIEF-Ab Science Q4 revenue rises to 544,000 euros

* Q4 revenue of 544,000 euros ($608,736) versus 496,000 euros year ago

27 Feb 2015

BRIEF-Ab Science announces positive Masitinib phase 2 results

* Announces positive phase 2 clinical study data of Masitinib in second-line metastatic stomach cancer

02 Feb 2015

BRIEF-AB Science says DSMB recommends continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis

* Data And Safety Monitoring Board (DSMB) recommends the continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis

13 Jan 2015

BRIEF-Ab Science reports positive follow-up results with masitinib

* Reports positive clinical study data in metastatic colorectal cancer

18 Dec 2014

BRIEF-AB Science SA advances SYK kinase inhibitor into full preclinical development

* Ultra-Selective SYK Kinase Inhibitor advanced into full preclinical development

28 Nov 2014

BRIEF-AB Science says data and safety monitoring board recommends continuation of phase 2 study with Masitinib in advanced Hepatocellular Carcinoma

* The data and safety monitoring board recommends the continuation of the phase 2 study with Masitinib in advanced hepatocellular carcinoma Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

12 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks